AR059030A1 - Combinacion de derivados de triazina y estimuladores de la secrecion de insulina - Google Patents
Combinacion de derivados de triazina y estimuladores de la secrecion de insulinaInfo
- Publication number
- AR059030A1 AR059030A1 ARP070100136A ARP070100136A AR059030A1 AR 059030 A1 AR059030 A1 AR 059030A1 AR P070100136 A ARP070100136 A AR P070100136A AR P070100136 A ARP070100136 A AR P070100136A AR 059030 A1 AR059030 A1 AR 059030A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- aryl
- halogen
- carboxy
- Prior art date
Links
- 230000003914 insulin secretion Effects 0.000 title abstract 3
- 150000003918 triazines Chemical class 0.000 title abstract 3
- -1 amino, hydroxyl Chemical group 0.000 abstract 37
- 125000003545 alkoxy group Chemical group 0.000 abstract 31
- 125000000217 alkyl group Chemical group 0.000 abstract 22
- 229910052736 halogen Inorganic materials 0.000 abstract 17
- 150000002367 halogens Chemical group 0.000 abstract 17
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 14
- 125000003282 alkyl amino group Chemical group 0.000 abstract 14
- 125000004414 alkyl thio group Chemical group 0.000 abstract 14
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 14
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 14
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 abstract 11
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Combinaciones de un derivado de la triazina y de un estimulador de la secrecion de insulina. Reivindicacion 1: Composicion farmacéutica caracterizada porque comprende, como principio activo: i) un estimulador de la secrecion de insulina, ii) un derivado de la triazina de la formula (1) en donde: R1, R2, R3 y R4 se seleccionan en forma independiente entre los grupos siguientes: -H; -alquilo C1-20 opcionalmente substituido con halogeno, alquilo C1-5, alcoxi C1-5 o cicloalquilo C3-8; - alquenilo C2-20 opcionalmente substituido con halogeno, alquilo C1-5 o alcoxi C1-5; -alquinilo C2-20 opcionalmente substituido con halogeno, alquilo C1-5 o alcoxi C1-5; -cicloalquilo C3-8 opcionalmente substituido con alquilo C1-5 o alcoxi C1-5; - heterocicloalquilo C3-8 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con alquilo C1-5 o alcoxi C1-5; -aril C6-14alquilo C1-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -heteroarilo C1-13 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -arilo C6-14 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxiIo, carboxi metilo o carboxietilo; R1 y R2, por un lado, y R3 y R4, por otro lado, pueden formar con el átomo de nitrogeno un anillo de n-miembros (n es entre 3 y 8) que contiene opcionalmente uno o más heteroátomos seleccionados entre N, O y S y puede estar substituido por uno o más de los grupos siguientes: amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14-alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; R5 y R6 se seleccionan en forma independiente entre los grupos siguientes: -H; -alquilo C1-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; - alquenilo C2-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; - alquinilo C2-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; - cicloalquilo C3-8 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; - heterocicloalquilo C3-8 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -arilo C6-14 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -heteroarilo C1-13 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -aril C6-14alquilo C1-5 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1- 5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; R5 y R6 pueden formar con el átomo de carbono al cual están unidos un anillo de m miembros (m es entre 3 y 8) que contiene opcionalmente uno o más heteroátomos seleccionados entre N, O y S y pueden estar substituidos con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo, o pueden formar con el átomo de carbono un residuo policíclico C10-30 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1- 5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo, R5 y R6 juntos pueden también representar grupo =O o =S, el átomo de nitrogeno de un grupo heterocicloalquilo o heteroarilo puede estar substituido con un grupo alquilo C1-5, cicloalquilo C3-8, arilo C6-14, aril C6-14alquilo C1-5 o acilo C1-6, y también las formas racémicas, tautomeras, enantiomeras, diastereoisomeros, epímeros y polimorfos, y mezclas de los mismos, y sus sales aceptables para uso farmacéutico, y uno o más excipientes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600342A FR2896157B1 (fr) | 2006-01-13 | 2006-01-13 | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059030A1 true AR059030A1 (es) | 2008-03-12 |
Family
ID=36648317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100136A AR059030A1 (es) | 2006-01-13 | 2007-01-12 | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8227465B2 (es) |
| EP (1) | EP1971339B1 (es) |
| JP (1) | JP5702911B2 (es) |
| KR (1) | KR20080091366A (es) |
| CN (1) | CN101355949A (es) |
| AR (1) | AR059030A1 (es) |
| AT (1) | ATE540682T1 (es) |
| AU (1) | AU2006334731B2 (es) |
| BR (1) | BRPI0620923A2 (es) |
| CA (1) | CA2636837C (es) |
| CY (1) | CY1112674T1 (es) |
| DK (1) | DK1971339T3 (es) |
| EA (1) | EA016649B1 (es) |
| ES (1) | ES2378469T3 (es) |
| FR (1) | FR2896157B1 (es) |
| IL (1) | IL192596A (es) |
| PL (1) | PL1971339T3 (es) |
| PT (1) | PT1971339E (es) |
| SI (1) | SI1971339T1 (es) |
| WO (1) | WO2007079914A2 (es) |
| ZA (1) | ZA200806938B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2355829T1 (sl) * | 2008-12-12 | 2015-03-31 | Poxel S.A.S. | Kombinacija inzulina z derivati triazina in njegova uporaba za zdravljenje diabetesa |
| FR2948028B1 (fr) * | 2009-07-17 | 2011-12-02 | Merck Sante Sas | Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine |
| RU2550798C2 (ru) * | 2011-05-12 | 2015-05-10 | Василий Иосифович Зоря | Способ стимуляции секреции инсулина |
| FR2987268B1 (fr) | 2012-02-28 | 2014-07-11 | Ammtek | Formulations liquides de sulfamides hypoglycemiants |
| TWI748945B (zh) * | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| MX2020003243A (es) | 2017-10-02 | 2020-09-18 | Poxel | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. |
| WO2019236844A1 (en) | 2018-06-06 | 2019-12-12 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| SG11202010322XA (en) | 2018-06-14 | 2020-11-27 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| USD945167S1 (en) | 2018-10-31 | 2022-03-08 | Kimberly-Clark Worldwide, Inc. | Paper sheet |
| JP7093473B2 (ja) * | 2019-12-13 | 2022-06-29 | 住友ファーマ株式会社 | 製造性及び溶出性に優れた小型錠剤 |
| US12280125B2 (en) | 2022-09-09 | 2025-04-22 | Imam Abdulrahman Bin Faisal University | Method for delivering insulin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
| FR2781152B1 (fr) | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
| WO2000078333A2 (en) * | 1999-06-21 | 2000-12-28 | Eli Lilly And Company | Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| EP1741447B1 (en) * | 2000-01-21 | 2013-09-18 | Novartis AG | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| FR2804113B1 (fr) | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| ITFI20010126A1 (it) | 2001-07-09 | 2003-01-09 | Molteni & C | Composizioni farmaceutiche per uso orale,contenenti,in combinazione,metformina e gliclazide |
| DE60219963T2 (de) * | 2002-01-25 | 2008-02-07 | Laboratorios Silanes, S.A. De C.V. | Pharmazeutische zusammensetzung, die zur glukosekontrolle im blut von patienten mit diabetes typ 2 eingesetzt wird |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20040147564A1 (en) * | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
| FR2853650B1 (fr) * | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
| KR20060119927A (ko) * | 2003-09-02 | 2006-11-24 | 프로시디온 리미티드 | 혈당 조절을 위한 조합 요법 |
-
2006
- 2006-01-13 FR FR0600342A patent/FR2896157B1/fr not_active Expired - Fee Related
- 2006-12-18 EA EA200801665A patent/EA016649B1/ru not_active IP Right Cessation
- 2006-12-18 BR BRPI0620923-8A patent/BRPI0620923A2/pt not_active Application Discontinuation
- 2006-12-18 SI SI200631268T patent/SI1971339T1/sl unknown
- 2006-12-18 US US12/160,637 patent/US8227465B2/en not_active Expired - Fee Related
- 2006-12-18 WO PCT/EP2006/012182 patent/WO2007079914A2/en not_active Ceased
- 2006-12-18 PT PT06829703T patent/PT1971339E/pt unknown
- 2006-12-18 DK DK06829703.5T patent/DK1971339T3/da active
- 2006-12-18 AT AT06829703T patent/ATE540682T1/de active
- 2006-12-18 AU AU2006334731A patent/AU2006334731B2/en not_active Ceased
- 2006-12-18 KR KR1020087019388A patent/KR20080091366A/ko not_active Ceased
- 2006-12-18 JP JP2008549780A patent/JP5702911B2/ja active Active
- 2006-12-18 ES ES06829703T patent/ES2378469T3/es active Active
- 2006-12-18 CN CNA2006800507984A patent/CN101355949A/zh active Pending
- 2006-12-18 EP EP06829703A patent/EP1971339B1/en not_active Not-in-force
- 2006-12-18 CA CA2636837A patent/CA2636837C/en not_active Expired - Fee Related
- 2006-12-18 PL PL06829703T patent/PL1971339T3/pl unknown
-
2007
- 2007-01-12 AR ARP070100136A patent/AR059030A1/es unknown
-
2008
- 2008-07-02 IL IL192596A patent/IL192596A/en active IP Right Grant
- 2008-08-12 ZA ZA200806938A patent/ZA200806938B/xx unknown
-
2012
- 2012-02-08 CY CY20121100133T patent/CY1112674T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007079914A2 (en) | 2007-07-19 |
| DK1971339T3 (da) | 2012-02-20 |
| AU2006334731B2 (en) | 2012-06-21 |
| SI1971339T1 (sl) | 2012-07-31 |
| JP5702911B2 (ja) | 2015-04-15 |
| CA2636837C (en) | 2013-12-10 |
| ZA200806938B (en) | 2010-02-24 |
| CA2636837A1 (en) | 2007-07-19 |
| ES2378469T3 (es) | 2012-04-12 |
| IL192596A (en) | 2015-07-30 |
| WO2007079914A3 (en) | 2007-09-07 |
| US8227465B2 (en) | 2012-07-24 |
| EP1971339A2 (en) | 2008-09-24 |
| IL192596A0 (en) | 2009-09-22 |
| CN101355949A (zh) | 2009-01-28 |
| ATE540682T1 (de) | 2012-01-15 |
| PT1971339E (pt) | 2012-02-20 |
| FR2896157B1 (fr) | 2008-09-12 |
| EA200801665A1 (ru) | 2008-12-30 |
| AU2006334731A1 (en) | 2007-07-19 |
| EP1971339B1 (en) | 2012-01-11 |
| CY1112674T1 (el) | 2016-02-10 |
| FR2896157A1 (fr) | 2007-07-20 |
| JP2009523139A (ja) | 2009-06-18 |
| KR20080091366A (ko) | 2008-10-10 |
| PL1971339T3 (pl) | 2012-04-30 |
| BRPI0620923A2 (pt) | 2011-11-29 |
| EA016649B1 (ru) | 2012-06-29 |
| US20100233255A1 (en) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059030A1 (es) | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| PE20141405A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR083161A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR045388A1 (es) | Inhibidores del c-kit imidazopiridinicos n3-sustituidos | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| PE20130010A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| CR9980A (es) | Imidazolinas 4,4,5,5 tetrasustituidas | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| UY31674A1 (es) | Derivado heterocíclico fusionado y su uso | |
| AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
| AR059031A1 (es) | Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR067996A1 (es) | Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros. | |
| AR043485A1 (es) | Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |